This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.02.056v1 49/24/2356    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Lawrenz, T. Articles by Kuhn, H. Search for Related Content PubMed Articles by Lawrenz, T. Articles by Kuhn, H.

CLINICAL RESEARCH: CARDIOMYOPATHY

Predictors of Complete Heart Block After Transcoronary Ablation of Septal Hypertrophy

Results of a Prospective Electrophysiological Investigation in 172 Patients With Hypertrophic Obstructive Cardiomyopathy

Thorsten Lawrenz, MD^_*,_*, Frank Lieder, MD, Markus Bartelsmeier, MD^_*, Christian Leuner, MD^_*, Bianca Borchert, MD^_*, Dorothee Meyer zu Vilsendorf, MD^_*, Claudia Strunk-Mueller, MD^_*, Jens Reinhardt, MD^_*, Andre Feuchtl, MD^_*, Christoph Stellbrink, MD, FACC^_* and Horst Kuhn, MD, FESC^_*

^_* Klinikum Bielefeld-Mitte, Department of Cardiology and Internal Intensive Care, Bielefeld, Germany
Raphaelsklinik Muenster GmbH, Medical Clinic I, Muenster, Germany.

Manuscript received October 31, 2006; revised manuscript received January 29, 2007, accepted February 20, 2007.

^_* Reprint requests and correspondence: Dr. Thorsten Lawrenz, Klinikum Bielefeld-Mitte, Akademisches Lehrkrankenhaus der WWU Munster, Klinik fur Kardiologie und Internistische Intensivmedizin, Teutoburger Strasse 50, D-33604 Bielefeld, Germany. (Email: thorsten.lawrenz{at}sk-bielefeld.de).

Objectives: This study analyzed changes in intracardiac conduction during transcoronary ablation of septal hypertrophy (TASH) to identify predictors for pacemaker dependency after TASH.

Background: Transcoronary ablation of septal hypertrophy is an accepted therapeutic option in hypertrophic obstructive cardiomyopathy (HOCM). However, atrioventricular conduction disorders, requiring permanent pacemaker implantation, remain a major adverse effect.

Methods: This study measured changes in intracardiac conduction in 172 consecutive patients during TASH by simultaneously recording electrophysiological parameters and correlated these parameters with the occurrence of complete heart block during continuous electrocardiographic monitoring for 8 days.

Results: Intraprocedural complete heart block occurred in 36 patients (20.1%) and was associated with a pre-existing bundle branch block (p = 0.010) or advanced age (p = 0.023). All patients with delayed complete heart block during follow-up (n = 15, 8.7%), occurring 1 to 6 days after TASH, showed lack of retrograde atrioventricular nodal conduction after TASH (p = 0.018). None of the patients with intact retrograde conduction after TASH developed delayed complete heart block. Further risk factors for delayed block were advanced age, intraprocedural complete heart block, and prolonged QRS duration before or after TASH (p < 0.05 for all). Permanent pacemaker implantation was performed in 20 patients.

Conclusions: Measurement of intracardiac conduction during TASH improves the safety of the procedure by enabling identification of patients who are at risk of complete heart block after TASH. The duration of prophylactic temporary pacemaker backup should be prolonged up to day 6 after TASH in patients at increased risk (patients with retrograde atrioventricular block and at least 1 additional risk factor).

Abbreviations and Acronyms   AH = atrium-to-proximal-His   AV = atrioventricular   ECG = electrocardiographic   EP = electrophysiology   HOCM = hypertrophic obstructive cardiomyopathy   HV = distal-His-to-ventricle   TASH = transcoronary ablation of septal hypertrophy

This article has been cited by other articles:

				D. H. Kwon, S. R. Kapadia, E. M. Tuzcu, C. M. Halley, E. Z. Gorodeski, R. J. Curtin, M. Thamilarasan, N. G. Smedira, B. W. Lytle, H. M. Lever, et al. Long-Term Outcomes in High-Risk Symptomatic Patients With Hypertrophic Cardiomyopathy Undergoing Alcohol Septal Ablation J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 432 - 438. [Abstract] [Full Text] [PDF]

				A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF]

				Writing Committee Members, A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF]